Dybly develops pharmaceutical products for patients affected by inflammatory and fibrotic diseases. The company owns several molecules with interesting activity and safety profiles. Dybly research is based on a sequence of hypothesis-driven small molecule drug design with validation by empirical data. Our scientific results demonstrate activity in the following pathways: BET-Bromodomain (inhibition); Apo A1 (upregulation); Inflammation (downregulation); Fibrosis (downregulation); Blood cancers: MML and AML (suppression of proliferation)
Indications we are interested in: Fibrotic diseases (lung, liver, heart), Blood cancers, Rheumatoid arthritis and other inflammatory diseases, diseases associated with senescence.